Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 2/20 | 0.37 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.35 |
| ▸ | ACACB | O00763 | 2/20 | 0.35 |
| ▸ | KIF11 | P52732 | 2/20 | 0.33 |
| ▸ | HHAT | Q5VTY9 | 1/20 | 0.33 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.33 |
| ▸ | ESR1 | P03372 | 1/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4240501 | 0.86 | TP53 (0.39) | TP53TRPV1ACACBKIF11HHAT | |
| SCHEMBL987510 | 0.76 | CA1 (0.48) | TRPV1ESR1ESR2 | |
| SCHEMBL985641 | 0.68 | CA1 (0.54) | TRPV1TSHR | |
| SCHEMBL986756 | 0.66 | PARP1 (0.45) | TP53TRPV1HHATTSHR | |
| SCHEMBL983328 | 0.65 | TSHR (0.47) | TRPV1HHATTSHR | |
| SCHEMBL987520 | 0.64 | MEN1 (0.45) | TRPV1ESR1ESR2TSHR | |
| SCHEMBL987136 | 0.64 | PARP1 (0.42) | TRPV1HHATTSHR | |
| SCHEMBL986456 | 0.63 | EDNRA (0.49) | TP53TRPV1TSHR | |
| SCHEMBL987237 | 0.63 | MTNR1B (0.51) | TP53ESR1ESR2TSHR | |
| SCHEMBL986042 | 0.61 | PARP1 (0.43) | TRPV1PDE4DTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090099133-A1 | Isoquinolines Derivatives as Igf-1R Inhibitors | ANALYTECON S.A. (CH) | 2009-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099133-A1 | Isoquinolines Derivatives as Igf-1R Inhibitors | IGF1R, IGFBP1, IGF2BP1 | TP53 2582/4885TRPV1 4805/4885ACACB 2003/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.